Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $96,495.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) insider Joshua Schafer sold 10,500 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total transaction of $96,495.00. Following the completion of the transaction, the insider owned 62,278 shares of the company’s stock, valued at $572,334.82. This represents a 14.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Joshua Schafer also recently made the following trade(s):

• On Friday, January 30th, Joshua Schafer sold 3,375 shares of Zevra Therapeutics stock. The stock was sold at an average price of $8.83, for a total transaction of $29,801.25.

Zevra Therapeutics Trading Up 2.9%

Zevra Therapeutics stock opened at $8.60 on Friday. Zevra Therapeutics, Inc. has a 12-month low of $6.19 and a 12-month high of $13.16. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.62 and a quick ratio of 8.57. The stock has a market capitalization of $484.18 million, a PE ratio of 18.30 and a beta of 0.99. The firm has a 50 day simple moving average of $8.68 and a 200-day simple moving average of $9.38.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The firm had revenue of $26.06 million during the quarter, compared to the consensus estimate of $26.64 million. As a group, equities research analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analyst Ratings Changes

ZVRA has been the topic of several research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, November 6th. Cantor Fitzgerald decreased their price target on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Finally, HC Wainwright set a $26.00 price target on Zevra Therapeutics in a report on Tuesday, December 30th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.80.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its stake in Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares during the period. Vanguard Group Inc. raised its stake in Zevra Therapeutics by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock valued at $29,323,000 after purchasing an additional 130,676 shares during the period. Nantahala Capital Management LLC boosted its position in shares of Zevra Therapeutics by 34.0% in the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after buying an additional 500,000 shares during the period. Rubric Capital Management LP boosted its position in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after buying an additional 740,584 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Zevra Therapeutics by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock valued at $10,948,000 after buying an additional 9,275 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.